Original ResearchThe Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials
Graphical abstract
Key Words
Abbreviations and Acronyms
Cited by (0)
The DCCT/EDIC studies were supported by cooperative grants (1982 to 1993, 2012 to 2017, and 2017 to 2022) from and contracts (1982 to 2012) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease (current grants U01 DK094176 and U01 DK094157), and the National Eye Institute, National Institute of Neurologic Disorders and Stroke, General Clinical Research Centers Program (1993 to 2007), and Clinical Translational Science Center Program (2006 to the present). Contributors included Abbott Diabetes Care, Animas, Bayer Diabetes Care, Becton Dickinson, Eli Lilly, Extend Nutrition, Insulet Corp., Lifescan, Medtronic Diabetes, Nipro Home Diagnostics, Nova Diabetes Care, Omron, Perrigo Diabetes Care, Roche Diabetes Care, and Sanofi-Aventis. Contributors provided free or discounted supplies or equipment to support participants’ adherence to the study but had no role in the DCCT/EDIC study. Dr. Budoff has received support from U.S. National Institutes of Health and General Electric. Dr. Raskin is a consultant for Reata Pharmaceutical; and has received support through his institution from Boehringer-Ingelheim Pharmaceutical and Gan & Lee Pharmaceutical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- ∗
A complete list of participants in the DCCT/EDIC Research Group is presented in the Supplemental Material published online for the article in N Engl J Med 2015;372:1722–33.